Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trametinib + sorafenib
- Development stage
- Discontinued
- Lead developer
- Moffitt Cancer Center
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Trametinib + sorafenib is a combination therapy investigated by the H. Lee Moffitt Cancer Center and Research Institute for the treatment of advanced hepatocellular carcinoma (HCC). Trametinib is a highly selective, reversible, allosteric inhibitor of MEK1 and MEK2, while sorafenib is a multikinase inhibitor that targets Raf kinases (C-Raf and B-Raf) and receptor tyrosine kinases involved in angiogenesis and tumor progression, such as VEGFR-1, -2, -3, PDGFR-beta, c-Kit, and FLT-3. The combination was evaluated in a Phase 1a/1b clinical trial (NCT02292173) to determine if dual inhibition of the MAPK pathway and other signaling cascades could overcome sorafenib resistance and improve outcomes in HCC. However, the study concluded that the combination showed limited anticancer activity in an unselected patient population, leading to the discontinuation of its development for this specific indication.
- Brand names
- MekinistNexavar
- Other names
- trametinibsorafenib
02
Targets
BRAF (B-Raf proto-oncogene, serine/threonine kinase)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRB (Platelet-derived growth factor receptor beta)MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)RAF1 (c-Raf-1 (Y340D/Y341D))MEK2 (Dual specificity mitogen-activated protein kinase kinase 2)VEGFR3 (Vascular endothelial growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)RET (Rearranged during transfection receptor tyrosine kinase)FLT3 (Fms related receptor tyrosine kinase 3)
Beyond the preview
Go deeper on trametinib + sorafenib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trametinib + sorafenib.